VANCOUVER, BC, — (November 6, 2019) – Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ATLED) (the “Company”) has granted a total of 3,500,000 stock options to certain officers, directors, consultants and an investor relations provider of the Company pursuant to the Company’s stock option plan. The stock options may be exercised at a price of $0.51 per option for a period of two years from the date of grant. Of the options granted, 400,000 will vest quarterly.
The Company also announces that it has entered into an agreement for a marketing campaign with CDMG Inc. to raise public awareness of the Company.
ON BEHALF OF THE BOARD OF DIRECTORS
Chief Executive Officer and President
About Isracann Biosciences Inc.
Isracann is an Israeli-based cannabis company focused on becoming a premier cannabis producer offering low-cost production targeting undersupplied, major European marketplaces. Based in Israel’s agricultural sector, Isracann will leverage its development within the most experienced country in the world with respect to cannabis research. The Company has secured agreements within Israel for medicinal marijuana cultivation. For more information visit: www.isracann.com.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ, materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission, and the Alberta Securities Commission.